Evidence map›Paper›PMID 34909712›Full record

ArticleJID innovations : skin science from molecules to population health2021

Skin Microbiota and Clinical Associations in Netherton Syndrome.

Veera Sillanpää, Tatiany Aparecida Teixeira Soratto, Elina Eränkö, Mauricio Barrientos-Somarribas, Katariina Hannula-Jouppi, Björn Andersson, Annamari Ranki

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JID innovations : skin science from molecules to population health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Crosstalk ofOncoTargets and therapy · 2025
    Article
  4. Review
  5. Review
  6. DNA and cell biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Veera SillanpääDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Tatiany Aparecida Teixeira SorattoDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
Elina EränköDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Mauricio Barrientos-SomarribasDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
Katariina Hannula-JouppiDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Björn AnderssonDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
Annamari RankiDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
University of Helsinki · FIKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Netherton syndrome (NS) is a rare, life-threatening syndrome caused by serine protease inhibitor Kazal-type 5 gene (

Indexed as

HFC, healthy family controlNS, Netherton syndromeScpA, staphopain ASspB, staphopain B

Identifiers

PMID34909712
PMCPMC8659401
OpenAlexW3135075901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.